Published in "The Lancet" Journal!


Dr. Kenneth Kim is a co author of an article in The Lancet Respiratory Medicine published today (May 10, 2022), titled  Efficacy and safety of intramuscular administration of AZD7442 (tixagevimab/cilgavimab) for early outpatient treatment of COVID-19.  This combination, called Evusheld has FDA EUA approval in the US for pre exposure prophylaxis in high risk individuals.  

Ark Clinical Research is currently running a prevention trial for Evusheld in pediatric patients.  Those who might qualify may call Ark clinical research at 562-997-1000.

Read FDA Approval

View available Studies


Good News!

Good News.tif

It is only through the efforts of clinical studies like these and our participants that we are able to improve the quality of life!

One of our recent clinical trials was published this February in The New England Journal of Medicine! This clinical trial was for nonhospitalized high-risk adults with Covid-19.

Results – “Treatment of symptomatic Covid-19 with nirmatrelvir plus ritonavir resulted in a risk of progression to severe Covid-19 that was 89% lower than the risk with placebo, without evident safety concerns.”

Read Article

View available Studies



California Small Business Day

Ark Clinical Research was selected as one of the 75 small businesses being recognized in California and received the “Small Business of the Year” award on August 18th, 2021.

“Resolved by Senator Dave Min, that he takes immense pleasure in congratulating Ark Clinical Research and its founder, Dr. Kenneth Kim, on selection as the 37th Senatorial District’s 2021 Small Business of the Year, commends it for providing valuable services to the people of the local area and contributing to the growth of California’s economy , and applauds its history of community support.

Ark Clinical Research is multi-therapeutic clinical research site located in Long Beach and Tustin, CA. Ark’s primary objective is to improve each patient's quality of life through the development of more effective therapies and devices. Consistently keeping its patients' well-being as top priority, Ark is dedicated to introducing innovative therapeutic regimens, treatments, devices, and delivery methods. Ark specializes in outpatient clinical trials and it has been assisting COVID-19 vaccine and treatment trials during the most important time.


California Small Business Day is the result of Assembly Resolution HR-57 that passed unanimously in 2000. This event brings together small business leaders, California state senators, assembly members and other state agency leaders in celebrating outstanding accomplishments and recognize the contribution of small business to the state of California.